[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
作者信息
Zhang Hui-juan, Zhang Xiao-tong, Zhang Li
出版信息
Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):862-4. doi: 10.3760/cma.j.issn.0529-5807.2012.12.020.
Abstract
摘要
相似文献
1
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].[具有转化型EML4-ALK融合基因的患者对克唑替尼耐药的机制]
Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):862-4. doi: 10.3760/cma.j.issn.0529-5807.2012.12.020.
2
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.受体配体触发的对阿来替尼的耐药性及其在EML4-ALK肺癌细胞中通过抑制Hsp90来规避耐药性的机制
Oncotarget. 2014 Jul 15;5(13):4920-8. doi: 10.18632/oncotarget.2055.
3
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.Hsp90 抑制剂 IPI-504 可迅速降低 EML4-ALK 水平，并在 ALK 驱动的 NSCLC 模型中诱导肿瘤消退。
Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.
4
[Study of EML4-ALK fusion gene as a biomarker in non-small cell lung cancer].
Zhonghua Bing Li Xue Za Zhi. 2011 Nov;40(11):788-90.
5
Crizotinib in the management of advanced-stage non-small-cell lung cancer.克唑替尼用于晚期非小细胞肺癌的治疗
Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.
6
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.在对阿来替尼耐药的两个存在 ALK 重排的非小细胞肺癌（NSCLC）患者中发现了一种新型的 HIP1-ALK 融合变体和 ALK I1171（I1171N/S）突变。
J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
7
[Clinical research of crizotinib in advanced non-small cell lung cancer].克唑替尼治疗晚期非小细胞肺癌的临床研究
Zhongguo Fei Ai Za Zhi. 2013 Jun;16(6):321-4. doi: 10.3779/j.issn.1009-3419.2013.06.09.
8
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.EML4-ALK 融合变体的差异蛋白稳定性和 ALK 抑制剂敏感性。
Clin Cancer Res. 2012 Sep 1;18(17):4682-90. doi: 10.1158/1078-0432.CCR-11-3260. Epub 2012 Aug 21.
9
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.重排的EML4-ALK融合转录本在循环血血小板中隔离，并能够在非小细胞肺癌中进行基于血液的克唑替尼反应监测。
Oncotarget. 2016 Jan 5;7(1):1066-75. doi: 10.18632/oncotarget.6279.
10
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.在不存在ALK突变的情况下对ALK抑制剂克唑替尼产生获得性耐药。
J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab.
Zotero 插件